RPCEC00000096暂停2 期
Evaluation of the Effect and Safety of ior® EPOCIM use in the prevention of cardiotoxicity in patients with Non-Hodking Lymphoma treated with anthracyclines.
Center of Molecular Immunology0 个研究点目标入组 88 人开始时间: 2010年6月11日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 暂停
- 发起方
- 入组人数
- 88
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled trial. Masking: Open. Control group: Active. Assignment: Other. Purpose: Treatment
入排标准
- 年龄范围
- 18 years 至 /A(No limit)（—）
- 性别
- All
入选标准
- •.Patients who met the diagnostic criteria.
- •.Patients of either sex with age greater than or equal to 18 years.
- •.Patients who give informed consent to participate in writing.
- •.Patients with hemoglobin below 13 g/dl.
排除标准
- •.Patients with uncontrolled hypertension.
- •.Patients with known risk or a history of venous or arterial thromboembolic disease.
- •.Severe cardiovascular disease:unstable angina,heart failure,aortic stenosis,endocarditis.
- •.Patients with poor acoustic window.
- •.Severe cerebrovascular disease. .Septic embolism.
- •.Chronic myeloproliferative diseases.
- •.Patients with known hypersensitivity to products derived from higher cells or hypersensitivity to human albumin.
研究者
相似试验
招募中
4 期
Effectiveness and safety of ior®EPOCIM in Chronic Kidney Disease patients in pre-dialysis.Anemia secondary to Chronic Kidney DiseaseRPCEC00000123CIMAB-Center of Molecular Immunology (CIM)425
已完成
4 期
Effectiveness and Safety of ior EPOCIM in patients with Chronic Renal Failure on dialysis methods.Chronic Renal Insufficiency.RPCEC00000082Center of Molecular Immunology(CIM)621
已完成
4 期
ior EPOCIM ® in the management of anemia of the preterm infant.Phase IV.Anemia of newborn pretermRPCEC00000149Center of Molecular Immunology(CIM)121
已完成
3 期
Effectiveness and safety of ior EPOCIM in anemia in premature infant.Anemia of preterm newbornRPCEC00000088Center of Molecular Immunology(CIM)72
尚未招募
2 期
ior®EPOCIM in post-COVID-19 convalescent patients with cardiovascular, renal and/or respiratory disordersCardiovascular, renal and respiratory disorders in convalescent patients from SARS-CoV-2 infectionCOVID-19SARS-CoV2Coronavirus InfectionsSARS VirusCoronaviridae InfectionsBetacoronavirus/complicationsRespiratory Tract InfectionsCardiovascular InfectionsKidney DiseasesRPCEC00000376Center of Molecular Immunology (CIM)135